*Needham & Co. "Based on a successful Phase III program in C. difficile infection establishing consistent superiority to vancomycin with respect to recurrence of infection and global cure, we believe the compound is likely to receive a favorable vote, followed by approval in May."
*Zacks "...we are quite optimistic regarding the approval of fidaxomicin". "...we are pleased to note that fidaxomicin scores better than the current available treatment options on many parameters."
*Hilary Kramer "Optimer is poised for double digit gains in 2011." "The big pharmaceutical companies are in desperate need for new blockbusters, ... we are going to see big pharma wanting a company like Optimer... it could be acquired at around $17 to $19 dollars a share. There is opportunities for billions of dollars of sales around the world for the drug to fight this disease.”
*Jefferies "Jefferies believes the upcoming FDA panel and PDUFA for Optimer Pharmaceuticals' fidaxomicin are likely to be positive and finds the stock inexpensive at current levels."
*Adam Feuerstein "Overall, the fidamoxicin data generated across two, large phase III studies are strong and should support a positive vote at next week's panel and full approval by the FDA on May 30."
It looks like people are taking full advantage of this mornings price drop and buying in for the move up. Would anyone like to venture an estimate of what kind of immediate bump up expected on approval?
These are the same Jackasses that were all gung-ho on orexigen. A lot of analysts were convinced to the point that they were putting millions of dollars into it on the long side, just to get it cut by 65 percent over night. The analysts do not know any more than we can figure out on our own.
FDA official was charged with insider trading today. This is the reason noone can predict the outcome of the FDA decision other than FDA staff. Manipulated decisions? Perhaps, but all of the data points toward approval.